Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.

Oxidative Stress and Nutrition Biomarkers (GERIOX)

Method of Measurement (Pre-analytical Tools)
Blood/Plasma
Biomarker Measured
Oxidative stress
Use
Susceptibility/risk
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results

The objective is to demonstrate a correlation between oxidative stress and nutrition biomarkers and the clinical evolution of patients complaining of cognitive impairments. In this study, the principal evaluation criteria will be the MMSE score evolution during the 60 months of the patients follow-up, measured during the routine visits scheduled approximately every 6 months, according to the french national authority for health recommendations. It will allow evaluating the correlation between the cognitive decline evolution measured by MMSE during the Alzheimer disease or related diseases method during the 2 years follow-up, and the oxidative stress blood markers.

Target Population/ Population Being Studied

People with Alzheimer disease or related diseases

Length of Current Trial
48 months
Number of Trial Participants

350

Estimated Trial Completion
December 2024
What is Required from Patients

blood draw, mild discomfort, in clinic visits

What is Required from the Health System

phlebotomist, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g.,mass spectrometer, protein assay kit, ELISA, western blot, or qPCR)

Sponsor

Hospices Civils de Lyon

“Influence of Oxidative Stress and Nutrition Biomarkers on the Cognitive Decline Evolution in Alzheimer Disease (GERIOX).” ClinicalTrials.gov. Accessed October 10, 2019. https://clinicaltrials.gov/ct2/show/NCT02800395?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&rank=6